Last reviewed · How we verify

NCT04694066

Qigong for Pre-frail and Frail Older Cancer Survivors

Completed NA Last updated 22 November 2022
What this trial tests

NA trial testing Qigong in Cancer in 28 participants. Completed in 30 June 2021.

Timeline
1 August 2019
Primary endpoint
28 February 2021
30 June 2021

Quick facts

Lead sponsorThe University of Hong Kong
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposesupportive care
Enrollment28
Start date1 August 2019
Primary completion28 February 2021
Estimated completion30 June 2021
Sites2 locations across Hong Kong

Drugs / interventions tested

Conditions studied

Sponsor

The University of Hong Kong

Who can join

Adults 65 to 85, any sex, with Cancer or Frailty. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To-date, there is no evidence on qigong's effects for improving well-being of pre-frail and frail older cancer survivors. Our aim is to conduct a pilot study for testing out the feasibility and acceptability of a qigong intervention to the elderly cancer survivors.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. A pilot randomized controlled trial using Baduanjin qigong to reverse frailty status among post-treatment older cancer survivors.
    Cheung DST, Chau PH, Lam TC, Ng AYM, et al · · 2022 · cited 24× · PMID 35272982 · DOI 10.1016/j.jgo.2022.02.014

Verify or expand the search:

Other trials of Qigong

Trials testing the same drug.

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other The University of Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04694066.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing